PMID- 32581289
OWN - NLM
STAT- MEDLINE
DCOM- 20201221
LR  - 20210624
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jun 24
TI  - Respiratory outcomes of metformin use in patients with type 2 diabetes and 
      chronic obstructive pulmonary disease.
PG  - 10298
LID - 10.1038/s41598-020-67338-2 [doi]
LID - 10298
AB  - Few studies investigated the respiratory outcomes of metformin use in patients 
      with coexistent type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary 
      disease (COPD). We want to compare the long-term respiratory endpoints of 
      metformin use and nonuse in patients with T2DM and COPD. This retrospective 
      cohort study enrolled patients with T2DM and COPD from Taiwan's National Health 
      Insurance Program between January 1, 2000, and December 31, 2012. Main outcomes 
      were hospitalized bacterial pneumonia, hospitalization for COPD, noninvasive 
      positive pressure ventilation (NIPPV), invasive mechanical ventilation (IMV), and 
      lung cancer. In total, 20,644 propensity score-matched metformin users and 
      nonusers were assessed. The adjusted hazard ratios (95% confidence intervals) of 
      metformin use relative to nonuse for bacterial pneumonia, hospitalization for 
      COPD, NIPPV, IMV, and lung cancer were 1.17 (1.11-1.23), 1.34 (1.26-1.43), 0.99 
      (0.89-1.10), 1.10 (1.03-1.17), and 1.12 (0.96-1.30). Metformin use also exhibited 
      significant dose-response relationship with respect to the risks of bacterial 
      pneumonia, hospitalization for COPD and IMV. Consistent results were found in the 
      sensitivity test. This nationwide cohort study demonstrated that in patients with 
      T2DM and COPD, metformin use was associated with higher risks of pneumonia, 
      hospitalization for COPD, and IMV. If patients with COPD use metformin, vigilance 
      with regard to their pulmonary condition may be required.
FAU - Yen, Fu-Shun
AU  - Yen FS
AD  - Dr. Yen's Clinic, No. 15, Shanying Road, Gueishan District, Taoyuan, 33354, 
      Taiwan.
FAU - Wei, James Cheng-Chung
AU  - Wei JC
AD  - Institute of Medicine, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. 
      Rd., South District, Taichung City, 40201, Taiwan.
AD  - Department of Medicine, Chung Shan Medical University Hospital, No. 110, Sec. 1, 
      Jianguo N. Rd., South District, Taichung City, 40201, Taiwan.
AD  - Graduate Institute of Integrated Medicine, China Medical University, Hsueh-Shih 
      Road, Taichung, 40402, Taiwan.
FAU - Yang, Yu-Cih
AU  - Yang YC
AD  - Management Office for Health Data, China Medical University Hospital, 3F, No. 
      373-2, Jianxing Road, Taichung, 40459, Taiwan.
AD  - College of Medicine, China Medical University, No. 110, Sec. 1, Jianguo N. Rd., 
      South District, Taichung City, 40201, Taiwan.
FAU - Hsu, Chih-Cheng
AU  - Hsu CC
AD  - Institute of Population Health Sciences, National Health Research Institutes, 
      Zhunan, No. 35, Keyan Rd., Zhunan Township, Miaoli, 35053, Taiwan. 
      cch@nhri.edu.tw.
AD  - Department of Health Services Administration, China Medical University, No. 91, 
      Xueshi Rd., North Dist., Taichung, 40402, Taiwan. cch@nhri.edu.tw.
AD  - Department of Family Medicine, Min-Sheng General Hospital, No. 168, ChingKuo Rd, 
      Taoyuan, 33044, Taiwan. cch@nhri.edu.tw.
FAU - Hwu, Chii-Min
AU  - Hwu CM
AD  - Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans 
      General Hospital, No. 201, Sec. 2 Shi-Pai Rd., Chung-Cheng Build. 11F Room522, 
      Taipei, 11217, Taiwan. chhwu@vghtpe.gov.tw.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200624
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Hospitalization/statistics & numerical data
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Longitudinal Studies
MH  - Lung Neoplasms/*epidemiology/etiology/therapy
MH  - Male
MH  - Metformin/*adverse effects
MH  - Middle Aged
MH  - Pneumonia, Bacterial/*epidemiology/etiology/therapy
MH  - Pulmonary Disease, Chronic Obstructive/*complications/therapy
MH  - Respiration, Artificial/statistics & numerical data
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Taiwan/epidemiology
PMC - PMC7314747
COIS- The authors declare no competing interests.
EDAT- 2020/06/26 06:00
MHDA- 2020/12/22 06:00
PMCR- 2020/06/24
CRDT- 2020/06/26 06:00
PHST- 2019/11/22 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/06/26 06:00 [entrez]
PHST- 2020/06/26 06:00 [pubmed]
PHST- 2020/12/22 06:00 [medline]
PHST- 2020/06/24 00:00 [pmc-release]
AID - 10.1038/s41598-020-67338-2 [pii]
AID - 67338 [pii]
AID - 10.1038/s41598-020-67338-2 [doi]
PST - epublish
SO  - Sci Rep. 2020 Jun 24;10(1):10298. doi: 10.1038/s41598-020-67338-2.